clinical trial · NCT07654829
Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)
Hereditary AngioedemaKVD900 600 mg
brief summary
This is a Phase 4, prospective, open-label trial to evaluate the safety and effectiveness of sebetralstat when used for STP for a qualifying procedures in patients 12 years of age or older with hereditary angioedema (HAE).
started
Jul 31, 2026
primary completion
Nov 29, 2027
completion
Dec 6, 2027
last updated
Jul 16, 2026
official title
A Phase 4, Open-Label Trial to Evaluate the Safety and Effectiveness of Sebetralstat When Used as Preprocedural Short-term Prophylaxis in Patients With Hereditary Angioedema
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol